ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
- Completion Follows FDA's Grant of Seven Years of Cinryze(TM) Marketing Exclusivity for Prophylaxis against Hereditary Angioedema - EXTON, Pa., Oct. 21 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced it has completed its acquisition of Lev Pharmaceutica...Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop
...f Medical Affairs. The following abstracts from studies supported by lev Pharmaceuticals, a company acquired by ViroPharma Incorporated in October 2...t considerations for patients with HAE, which was paid for and organized by lev Pharmaceuticals. Abstract book page 46: Subcutaneous ...Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
...s expected to conclude in the second half of 2007. lev has also initiated two open label studies to provi...,000 people with HAE in the United States. About lev Pharmaceuticals, Inc. lev is a biopharmaceutical company focused on developi...